VANCOUVER, British Columbia, June 17, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) announced the appointment of Joseph Leung (“Joseph”) as its new Chief Financial Officer (“CFO”) and Corporate Secretary. Joseph will be replacing Dr. Camie Chan, who has been serving as the Company’s interim CFO and Corporate Secretary.
Joseph has accumulated nearly two decades of experience in the field of financial management and accounting, specializing in mergers and acquisitions, compliance and risk management, and the development and monitoring of control systems.
Joseph most recently served as Head of Financial Planning and Control at Transport International Holdings Limited, a company publicly listed on the Hong Kong Stock Exchange, where he oversaw and managed the group’s corporate actions, fundraising activities, along with the formulation and monitoring of the budget process. Prior to that, Joseph was the CFO and Company Secretary for another publicly listed company on the Hong Kong Stock Exchange. Over the course of his career, Joseph participated in numerous capital market transactions including mergers and acquisitions, debt offerings as well as initial public offerings. Joseph began his career articling with Ernst & Young Hong Kong before he moved on to enrich his expertise on capital market transactions in the Capital Market Services Group at PricewaterhouseCoopers (PwC) Hong Kong. He is a Certified Public Accountant and holds a Bachelor of Arts (Honours) in Accounting from the University of British Columbia.
“We are pleased to welcome Joseph as our CFO,” said Dr. Ronald Li, Co-founder & CEO of Novoheart. “With his broad and extensive experience in capital market transactions including IPOs, acquisitions and disposals, Joseph will bring invaluable expertise to the strategic planning of the company’s fundraising and financial management. We are thrilled to have him on board as the company enters a new phase of growth.”
ABOUT NOVOHEART HOLDINGS INC.
Novoheart is a global stem cell biotechnology company dedicated to human heart engineering with offices and laboratories in the United States, Canada and Hong Kong. Novoheart’s scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeartTM platform, including the world’s first human mini-heart “novoHeartTM” (otherwise known as a “human heart-in-a-jar”) that is fully capable of pumping and ejecting fluid. Novoheart believes that its proprietary platform uniquely positions the Company to enter into commercial partnerships with leading pharmaceuticals and research institutions to deliver pre-clinical cardiotoxicity screening and to develop custom-tailored engineered heart constructs for disease modeling and drug discovery. Novoheart also believes that the MyHeartTM platform is well-positioned for the potential development of cell-based cardiac regenerative therapies with superior safety and efficacy.
Common shares of Novoheart is traded on the TSX Venture Exchange under the symbol “NVH”.
For further information please contact:
Novoheart Holdings Inc.
Suite 1430, 800 West Pender Street
Vancouver, British Columbia
V6C 2V6
Ronald Li
Chief Executive Officer
info@novoheart.com
(604) 398-3170
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company’s future plans, its goals and expectations, and the potential applications its MyHeartTM platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.’s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.
